WuXi companies left out of latest version of Biosecure Actnews2025-10-10T19:20:46+00:00October 10th, 2025|Endpoints News|
New study suggests patients with anti-AAV antibodies may still receive gene therapynews2025-10-10T18:47:55+00:00October 10th, 2025|Endpoints News|
Head of FDA’s orphan drug office is removed from rolenews2025-10-10T18:10:10+00:00October 10th, 2025|Endpoints News|
J&J is in discussions to buy out Protagonist Therapeutics — reportnews2025-10-10T17:04:46+00:00October 10th, 2025|Endpoints News|
White House, AstraZeneca expected to announce drug price dealnews2025-10-10T16:51:36+00:00October 10th, 2025|Endpoints News|
Biopharma is wagering billions of dollars that CAR-T therapy can be easier. Will it work this time?news2025-10-10T15:37:23+00:00October 10th, 2025|Endpoints News|
Cabaletta Bio says small number of autoimmune patients responded to its CAR-T without toxic preconditioningnews2025-10-10T14:35:34+00:00October 10th, 2025|Endpoints News|
Satellos to run a trial for Duchenne pill in kids; Idorsia raises $81Mnews2025-10-10T14:16:48+00:00October 10th, 2025|Endpoints News|
French non-profit bets on Duchenne gene therapy that comes in lower dose than Elevidysnews2025-10-10T13:57:21+00:00October 10th, 2025|Endpoints News|
Bristol Myers joins in vivo CAR-T race with $1.5B Orbital acquisitionnews2025-10-10T11:28:23+00:00October 10th, 2025|Endpoints News|
